Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.
创建时间：
2023-03-15
